The use of potent multiagent chemotherapy protocols has resulted in increased opportunities for potentially curative resection, including resection for locally advanced pancreatic cancer (LAPC).
1,2 However, identifying the patients who would benefit from conversion surgery for LAPC has been a matter of debate during the past decade.
3,4 Evidence-based guidelines for conversion surgery after induction chemotherapy are currently lacking. This study therefore focused on the preoperative factors predictive of overall survival for patients with resected LAPC after induction FOLFILINOX and established a prognostic model with these factors that may guide optimal treatment for LAPC.
5 …